Abstract: Multiple myeloma (MM) is a malignant plasmacyte disease that often presents with symptoms such as bone pain and anemia. Currently, there is an increasing number of literature reports on malignant tumors combined with hyperamylasemia, but this is more common in tumors such as gastric cancer, and MM with hyperamylasemia is clinically rare and has not been found in plateau areas. Due to the complex clinical manifestations of MM patients with hyperamylasemia, there is no standard treatment therapy. There is no literature report on the use of daretuumab in combination. Based on the results of the retrospective analysis of the first case of MM with hyperamylasemia in a plateau area, it is recommended that clinicians in plateau areas take amylase level as a sensitive indicator to evaluate the severity of MM in order to reduce the misdiagnosis rate of MM and provide a new treatment option for the promotion and application of MM with hyperamylasemia.